Steffen Rausch
Overview
Explore the profile of Steffen Rausch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
830
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lawaczeck L, Rudiger A, Hennenlotter J, Hammes J, Spingler V, Walz S, et al.
J Cancer Res Clin Oncol
. 2025 Mar;
151(3):101.
PMID: 40047924
Purpose: Interdisciplinary tumor boards (ITB) are essential in optimizing treatment recommendations for metastatic castration-resistant prostate cancer (mCRPC) by incorporating oncology guidelines, clinical trials, and patient-specific factors to ensure individualized care....
2.
3.
Giannini G, Kafka M, Neuwirt H, Artamonova N, di Santo G, Virgolini I, et al.
Clin Genitourin Cancer
. 2024 Nov;
23(1):102260.
PMID: 39608079
Background: Lu PSMA therapy is increasingly used for metastatic castration-resistant prostate cancer (mCRPC) treatment. However, data on its efficacy and safety in patients previously treated with Ra remain limited. Methods:...
4.
Thone M, Lask J, Hennenlotter J, Saar M, Tsaur I, Stenzl A, et al.
Urolithiasis
. 2024 Nov;
52(1):166.
PMID: 39579203
Climate change poses a significant global health challenge, with medical procedures contributing substantially to CO emissions. Urology, as part of the broader healthcare sector, has begun integrating Planetary Health concepts...
5.
Garaz R, Amend B, Stenzl A, Bedke J, Hennenlotter J, Rochwarger A, et al.
Int Urol Nephrol
. 2024 Oct;
57(2):355-362.
PMID: 39377995
Purpose: Collagen fleece grafting (CFG) is the recommended treatment for severe Peyronie's disease (PD) curvature (> 60°), but its efficacy in mild/moderate curvatures remains uncertain. This study evaluated CFG in...
6.
Feger M, Hammerschmidt K, Liesche I, Rausch S, Alber J, Foller M
Biomed Pharmacother
. 2024 Sep;
180:117475.
PMID: 39332190
Bone cells produce fibroblast growth factor 23 (FGF23), a hormone regulating renal phosphate and vitamin D homeostasis, and a paracrine factor produced in further tissues. Chronic kidney disease and cardiovascular...
7.
Kunath F, Heidegger I, Heck M, Mayr R, Becker C, Rausch S
Urologie
. 2024 Aug;
63(9):899-907.
PMID: 39107624
The rapid development of molecular medicine has opened up new perspectives for the diagnosis and treatment of urological tumors. Urology faces the challenge of effectively treating advanced cancer, especially in...
8.
Kielbik A, Hoffmans T, Amend B, Stenzl A, Maas M, Rausch S, et al.
Urol Int
. 2024 Jun;
108(6):493-499.
PMID: 38901420
Introduction: Partial cystectomy aims to preserve bladder function, yet its urodynamic impacts remain unclear. We investigate these effects using an ex vivo porcine model, evaluating bladder volume, compliance, and wall...
9.
Lawaczeck L, Rudolph J, Norz V, Tsaur I, Rausch S
Expert Rev Anticancer Ther
. 2024 May;
24(7):513-523.
PMID: 38709157
Introduction: Climate change and global warming are an omnipresent topic in our daily lives. Planetary health and oncology represent two critical domains within the broader spectrum of healthcare, each addressing...
10.
Klumper N, Tran N, Zschabitz S, Hahn O, Buttner T, Roghmann F, et al.
J Clin Oncol
. 2024 Apr;
42(20):2446-2455.
PMID: 38657187
Purpose: The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset....